medRxiv preprint doi: https://doi.org/10.1101/2020.08.05.20168930; this version posted August 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Genomic epidemiology reveals transmission patterns and 1 dynamics of SARS-CoV-2 in Aotearoa New Zealand 2

- Jemma L Geoghegan^{1,2}, Xiaoyun Ren², Matthew Storey², James Hadfield³, Lauren Jelley², Sarah 4
- Jefferies², Jill Sherwood², Shevaun Paine², Sue Huang², Jordan Douglas⁴, Fábio K Mendes⁴, 5
- Andrew Sporle^{5,6}, Michael G Baker⁷, David R Murdoch⁸, Nigel French⁹, Colin R Simpson^{10,11}, David 6
- Welch⁴, Alexei J Drummond⁴, Edward C Holmes¹², Sebastián Duchêne¹³, Joep de Ligt² 7
- 8
- 9 ¹Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
- ²Institute of Environmental Science and Research, Wellington, New Zealand. 10
- ³Fred Hutchinson Cancer Research Centre, Seattle, Washington, USA. 11
- ⁴Centre for Computational Evolution, School of Computer Science, University of Auckland, 12
- Auckland, New Zealand. 13
- 14 ⁵Department of Statistics, University of Auckland, New Zealand.
- ⁶McDonaldSporle Ltd., Auckland, New Zealand. 15
- 16 ⁷Department of Public Health, University of Otago, Wellington, New Zealand.
- ⁸Department of Pathology and Biomedical Science, University of Otago, Christchurch, New 17
- Zealand. 18
- 19 ⁹School of Veterinary Science, Massey University, Palmerston North, New Zealand.
- ¹⁰School of Health, Faculty of Health, Victoria University of Wellington, Wellington, New Zealand. 20
- ¹¹Usher Institute, University of Edinburgh, Edinburgh, United Kingdom. 21
- ¹²Marie Bashir Institute for Infectious Diseases and Biosecurity. School of Life and Environmental 22
- 23 Sciences and School of Medical Sciences, The University of Sydney, Sydney, New South Wales,
- Australia. 24
- ¹³Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty 25
- 26 Institute for Infection and Immunity, Melbourne, Victoria, Australia.
- 27 Author for correspondence: jemma.geoghegan@otago.ac.nz
- 28 Keywords: SARS-CoV-2; COVID-19; coronavirus; genomics; phylodynamics; phylogenetics; virus
- 29 evolution, infeptious of sease and warden certified by peer review and should not be used to guide clinical practice.

Abstract 30

New Zealand, a geographically remote Pacific island with easily sealable borders, implemented a 31 nation-wide lockdown of all non-essential services to curb the spread of COVID-19. New Zealand 32 33 has now effectively eliminated the virus, with low numbers of new cases limited to new arrivals in managed guarantine facilities at the border. Here, we generated 649 SARS-CoV-2 genome 34 sequences from infected patients in New Zealand with samples collected between 26 February 35 and 22 May 2020, representing 56% of all confirmed cases in this time period. Despite its 36 remoteness, the viruses imported into New Zealand represented nearly all of the genomic 37 diversity sequenced from the global virus population. The proportion of D614G variants in the 38 virus spike protein increased over time due to an increase in their importation frequency, rather 39 than selection within New Zealand. These data also helped to quantify the effectiveness of public 40 41 health interventions. For example, the effective reproductive number, Re, of New Zealand's largest 42 cluster decreased from 7 to 0.2 within the first week of lockdown. Similarly, only 19% of virus 43 introductions into New Zealand resulted in a transmission lineage of more than one additional 44 case. Most of the cases that resulted in a transmission lineage originated from North America, 45 rather than from Asia where the virus first emerged or from the nearest geographical neighbour, 46 Australia. Genomic data also helped link more infections to a major transmission cluster than 47 through epidemiological data alone, providing probable sources of infections for cases in which 48 the source was unclear. Overall, these results demonstrate the utility of genomic pathogen 49 surveillance to inform public health and disease mitigation.

50

Main Text 51

52 New Zealand is one of a handful of countries that aimed to eliminate coronavirus disease 19 53 (COVID-19). The disease was declared a global pandemic by the World Health Organisation (WHO) on 11 March 2020. The causative virus, severe acute respiratory syndrome coronavirus 2 54 (SARS-CoV-2)¹, was first identified and reported in China in late December 2019, and is the 55 seventh coronavirus known to infect humans, likely arising through zoonotic transmission from 56 wildlife². Because of its relatively high case fatality rate³⁻⁵, and virus transmission from 57 asymptomatic or pre-symptomatic individuals^{6,7}, SARS-CoV-2 presents a significant public health

- 58 challenge. Due to its high rate of transmission, morbidity and mortality, SARS-CoV-2 has resulted 59
- 60 in world-wide lockdowns, economic collapses and led to healthcare systems being overrun.

Since the publication of the first SARS-CoV-2 genome on 10 January 2020⁸, there has been a 61

- 62 substantial global effort to contribute and share genomic data to inform local and international
- communities about key aspects of the pandemic⁹. Analyses of genomic data have played an 63
- 64 important role in tracking the epidemiology and evolution of the virus, often doing so in real time¹⁰,

and leading to a greater understanding of COVID-19 outbreaks globally¹¹⁻¹⁵.

New Zealand reported its first case on 26 February 2020 and within a month implemented a

67 stringent, country-wide lockdown of all non-essential services. To investigate the origins, time-

- scale and duration of virus introductions into New Zealand, the extent and pattern of viral spread
- across the country, and to quantify the effectiveness of intervention measures, we generated
- vhole genome sequences from 56% of all documented SARS-CoV-2 cases from New Zealand
- and combined these with detailed epidemiological data.





73 Figure 1. (a) Number of laboratory-confirmed cases by reported date, both locally acquired (grey) and linked to overseas travel (blue) in New Zealand, highlighting the timing of public health alert 74 levels 1-4 ('eliminate', 'restrict', 'reduce', 'prepare') and national border closures. The number of 75 76 genomes sequenced in this study is shown over time. (b) Map of New Zealand's District Health 77 Boards shaded by the incidence of laboratory-confirmed cases of COVID-19 per 100,000 people. 78 (c) Number of laboratory-confirmed cases per District Health Board (DHB) versus number of 79 genomes sequenced, indicating Spearman's p, where asterisks indicate statistical significance (p<0.0001). 80

- Table 1. Demographic data for confirmed (n=1178) and probable (n=350) cases of SARS-CoV-2
- in New Zealand between 26 February and 1 July 2020. The percentage of genomes sequenced in
- each category is shown.

Age group	Number of cases	Deceased	Percentage of genomes in data set
0 to 9	37	0	6%
10 to 19	122	0	38%
20 to 29	365	0	45%
30 to 39	238	0	39%
40 to 49	221	0	42%
50 to 59	248	0	44%
60 to 69	180	3	45%
70 to 79	78	7	45%
80 to 89	30	7	50%
90+	9	5	56%

Gender	Number of cases	Percentage of cases	Percentage of genomes in data set
Female	848	55%	42%
Male	680	45%	41%

Ethnicity	Number of cases	Percentage of cases	Percentage of genomes in data set
European or other	1067	70%	46%
Asian	210	14%	27%
Māori	130	9%	42%
Pacific peoples	81	5%	35%
Middle Eastern / Latin American / African	33	2%	42%
Unknown	7	0.50%	86%

Transmission type	Number of cases	Percentage of cases	Percentage of genomes in data set
Imported cases	572	37%	48%
Locally-acquired cases	956	63%	39%

90 Between 26 of February and 1 July 2020 there were a total of 1,178 laboratory-confirmed cases and a further 350 probable cases of SARS-CoV-2 in New Zealand (a probable case is defined as 91 a person who has returned a negative laboratory result or could not be tested, but the medical 92 officer of health has assigned the case classification based on exposure history and clinical 93 94 symptoms). Of these combined laboratory-confirmed and probable cases, 55% were female and 45% were male, with the highest proportion of cases in the 20-29 age group (Table 1). Many 95 cases were linked to overseas travel (37%). Geographic locations in New Zealand with the highest 96 97 number of reported cases did not necessarily reflect the human population size or density in that region, with the highest incidence reported in the Southern District Health Board (DHB) region 98 rather than in highly populated cities (Figure 1). The number of laboratory-confirmed cases 99 peaked on 26 March 2020, the day after New Zealand instigated an Alert Level 4 lockdown - the 100 most stringent level, ceasing all non-essential services and stipulating that the entire population 101 102 self-isolate (Figure 1). From 23 May 2020, New Zealand experienced 25 consecutive days with no new reported cases until 16 June, when new infections, linked to overseas travel, were 103 diagnosed. All subsequent new cases have been from patients in managed guarantine facilities. 104

We sequenced a total of 649 virus genomes from samples taken between 26 February (first reported case) and 22 May 2020 (to date, the last confirmed case unassociated with managed quarantine facilities). This represented 56% of all New Zealand's confirmed cases sampled during that period. The data generated originated from the 20 DHBs from across New Zealand. DHBs submitted between 0.1% and 81% of their positive samples to the Institute of Environmental Science and Research (ESR), Wellington, for sequencing. Despite this disparity, a strong nationwide spatial representation was achieved (Figure 1).

Notably, the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand represented 112 nearly all of the genomic diversity present in the global viral population, with nine second-level A 113 and B lineages from a recently proposed global SARS-CoV-2 genomic nomenclature¹⁶ identified. 114 This high degree of genomic diversity was observed throughout the country (Figure 2). The SARS-115 CoV-2 genomes sampled in New Zealand comprised 24% aspartic acid (S^{D614}) and 73% glycine 116 (S^{G614}) at residue 614 in the spike protein (Figure 2). Preliminary studies suggest that the D614G 117 mutation can enhance viral infectivity in cell culture¹⁷. Nevertheless, it is noteworthy that the 118 increase in glycine in New Zealand samples is due to multiple importation events of this variant 119 rather than selection for this mutation within New Zealand. We also inferred a weak yet significant 120 121 temporal signal in the data, reflecting the low mutation rate of SARS-CoV-2, which is consistent with findings reported elsewhere (Figure 2). 122



123

124 Figure 2. (a) Root-to-tip regression analysis of New Zealand (blue) and global (grey) SARS-CoV-2 sequences, with the determination coefficient, r^2 (an asterisk indicates statistical significance; 125 p<0.05). (b) Maximum-likelihood time-scaled phylogenetic analysis of 649 viruses sampled from 126 127 New Zealand (coloured circles) on a background of 1000 randomly subsampled viruses from the 128 globally available data (grey circles). Viruses sampled from New Zealand are colour-coded according to their genomic lineage¹⁶. (c) The number of SARS-CoV-2 genomes sampled in New 129 Zealand within each lineage¹⁶. (d) The sampling location and proportion of SARS-CoV-2 genomes 130 sampled from each viral genomic lineage is shown on the map of New Zealand. (e) The frequency 131 132 of D (blue) and G (red) amino acids at residue 614 on the spike protein over time.

133 Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649 cases considered. Of these, we estimated that 24% (95% CI: 23-30) led to 134 only one other secondary case (i.e. singleton) while just 19% (95% CI: 15-20) of these introduced 135 136 cases led to ongoing transmission, forming a transmission lineage (i.e. onward transmission to more than one individual; Figure 3). The remainder (57%) did not lead to a transmission event. 137 New Zealand transmission lineages most often originated in North America, rather than in Asia 138 where the virus first emerged, likely reflecting the high prevalence of the virus in North America 139 during the sampling period. By examining the time of the most recent common ancestor, or 140 TMRCA, of the samples, we found no evidence that the virus was circulating in New Zealand 141 before the first reported case on 26 February. Finally, we found that detection was more efficient 142 (i.e. fewer cases were missed) later in the epidemic in that the detection lag (the duration of time 143 from the first inferred transmission event to the first detected case) declined with the age of 144 145 transmission lineages (as measured by the time between the present and the TMRCA; Figure 3).





166 The largest clusters in New Zealand were often associated with social gatherings such as weddings, hospitality and conferences¹⁸. The largest cluster, which comprised lineage B.1.26, 167 most likely originated in the USA according to epidemiological data, and significant local 168 169 transmission in New Zealand was probably initiated by a superspreading event at a wedding in Southern DHB (geographically the most southern DHB) prior to lockdown. Examining the rate of 170 transmission of this cluster enables us to quantify the effectiveness of the lockdown. Its effective 171 reproductive number, Re, decreased over time from 7 at the beginning of the outbreak (95% 172 credible interval, CI: 3.7-10.7) to 0.2 (95% CI: 0.1-0.4) by the end of March (Figure 4). The 173 sampling proportion of this cluster, a key parameter of the model, had a mean of 0.75 (95% CI: 174 0.4-1), suggesting sequencing captured the majority of cases in this outbreak. In addition, 175 analysis of genomic data has linked five additional cases to this cluster that were not identified in 176 the initial epidemiological investigation, highlighting the added value of genomic analysis. This 177 178 cluster, seeded by a single-superspreading event that resulted in New Zealand's largest chain of transmission, illustrates the link between micro-scale transmission to nation-wide spread (Figure 179 180 4).





198 The dramatic decrease in R_e of this large cluster coupled with the relatively low number of virus introductions that resulted in a transmission lineage suggests that implementing a strict and early 199 lockdown in New Zealand rapidly reduced multiple chains of virus transmission. As New Zealand 200 continues to remain free of COVID-19 community transmission, but with positive cases still 201 detected amongst individuals guarantined at the border reflecting high virus incidence in other 202 203 localities, it is imperative that ongoing genomic surveillance is an integral part of the national response to monitor any re-emergence of the virus, particularly when border restrictions might 204 205 eventually be eased.

206

207 Methods

208 **Ethics statement**. Nasopharyngeal samples testing positive for SARS-CoV-2 by real-time

209 polymerase chain reaction (RT-PCR) were obtained from public health medical diagnostics

210 laboratories located throughout New Zealand. All samples were de-identified before receipt by the

researchers. Under contract for the Ministry of Health, ESR has approval to conduct genomic

212 sequencing for surveillance of notifiable diseases.

213 Genomic sequencing of SARS-CoV-2. A total of 733 laboratory-confirmed samples of SARS-

214 CoV-2 were received by ESR for whole genome sequencing. Viral extracts were prepared from

215 respiratory tract samples where SARS-CoV-2 was detected by RT-PCR using WHO

recommended primers and probes targeting the E and N gene. Extracted RNA from SARS-CoV-2

217 positive samples were subject to whole genome sequencing following the ARTIC network

218 protocol (V1 and V3) and the New South Wales (NSW) primer set¹⁵.

Briefly, three different tiling amplicon designs were used to amplify viral cDNA prepared with SuperScript IV. Sequence libraries were then constructed using Illumina Nextera XT for the NSW primer set or the Oxford Nanopore ligation sequencing kit for the ARTIC protocol. Libraries were sequenced using Illumina NextSeq chemistry or R9.4.1 MinION flow cells, respectively. Nearcomplete (>90% recovered) viral genomes were subsequently assembled through reference mapping. Steps included in the pipeline are described in detail online (https://github.com/ESR-NZ/NZ_SARS-CoV-2_genomics).

226 The reads generated with Nanopore sequencing using ARTIC primer sets (V1 and V3) were

mapped and assembled using the ARTIC bioinformatics medaka pipeline (v 1.1.0)¹⁹. For the NSW

primer set, raw reads were quality and adapter trimmed using trimmomatic (v 0.36)²⁰. Trimmed

paired reads were mapped to a reference using the Burrows-Wheeler Alignment tool²¹. Primer

sequences were masked using iVar (v 1.2)²². Duplicated reads were marked using Picard (v

231 2.10.10)²³ and not used for SNP calling or depth calculation. Single nucleotide polymorphisms

232 (SNPs) were called using bcftools mpileup (v 1.9)²⁴. SNPs were quality trimmed using vcflib (v

- 1.0.0)²⁵ requiring 20x depth and overall quality of 30. Positions that were less than 20x were
- masked to N in the final consensus genome. Positions with an alternative allele frequency
- between 20% to 79% were also masked to N. In total, 649 sequences passed our quality control
- 236 (BioProject: PRJNA648792; a list of genomes and their sequencing methods are provided in
- 237 Supplementary Table 1).

238 Phylogenetic analysis of SARS-CoV-2.

SARS-CoV-2 sequences from New Zealand, together with 1,000 genomes uniformly sampled at random from the global population from the ~50,000 available sequences from GISAID²⁶ (June 2020), were aligned using MAFFT(v 7)²⁷ using the FFT-NS-2 algorithm. A maximum likelihood phylogenetic tree was estimated using IQ-TREE (v 1.6.8)²⁸, utilising the Hasegawa-Kishino-Yano (HKY+ Γ)²⁹ nucleotide substitution model with a gamma distributed rate variation among sites (the best fit model was determined by ModelFinder³⁰), and branch support assessment using the ultrafast bootstrap method³¹. We regressed root-to-tip genetic divergence against sampling dates

- to investigate the evolutionary tempo of our SARS-CoV-2 samples using TempEst (v 1.5.3)³².
- Lineages were assigned according to the proposed nomenclature¹⁶ using pangolin
- 248 (https://github.com/hCoV-2019/pangolin). To depict virus evolution in time, we used Least
- 249 Squares Dating³³ to estimate a time-scaled phylogenetic tree using the day of sampling.

With the full set of New Zealand sequences, we used a time-aware coalescent Bayesian 250 exponential growth model available in BEAST (v 1.10.4)³⁴. The HKY+F model of nucleotide 251 substitution was again used along with a strict molecular clock. Because the data did not display 252 a strong temporal signal, we used an informative prior reflecting recent estimates for the 253 substitution rate of SARS-CoV-2³⁵. The clock rate had a Γ prior distribution as a prior with a mean 254 of 0.8 x 10^{-3} subs/site/year and standard deviation of 5 x 10^{-4} (parameterised using the shape and 255 rate of the Γ distribution). Parameters were estimated using Bayesian Markov Chain Monte Carlo 256 (MCMC) framework, with 2 x 10⁸ steps-long chains, sampling every 1 x 10⁵ steps and removing 257 the initial 10% as burn-in. Sufficient sampling was assessed using Tracer (v 1.7.1)³⁶, by verifying 258 that every parameter had effective sampling sizes above 200. Virus sequences were annotated as 259 260 'imported' (including country of origin) or 'locally acquired', according to epidemiological data provided by EpiSurv³⁷. From a set of 1,000 posterior trees, we estimated a number of statistics 261 using NELSI³⁸. We determined the number of introductions of the virus into New Zealand as well 262 263 as the changing number of local transmission lineages through time, with the latter defined as two 264 or more New Zealand SARS-CoV-2 cases that descend from a shared introduction event of the virus into New Zealand³⁹. Importation events that led to only a single case rather than a 265 transmission lineage are referred to as 'singletons'. For each transmission lineage and singleton, 266 we inferred the TMRCA. 267

To estimate R_e through time we analysed New Zealand sequences from the clade identified to be associated with a wedding. We used a Bayesian birth-death skyline model using BEAST (v 2.5)⁴⁰, estimating R_e for two time-intervals, as determined by the model, and with the same parameter settings as above. We assumed an infectious period of 10 days, which is consistent with global epidemiological estimates⁴¹.

273

274 Online Supplementary Material

Supplementary Table 1. A list of genomes and which amplification and sequencing method wasused in for each case.

277

278 Acknowledgements

This work was funded by the Ministry of Health of New Zealand, New Zealand Ministry of 279 Business, Innovation and Employment COVID-19 Innovation Acceleration Fund (CIAF-0470), ESR 280 Strategic Innovation Fund and the New Zealand Health Research Council (20/1018). We thank the 281 ATRIC network for making their protocols and tools openly available and specifically Josh Quick 282 for sending the initial V1 and V3 amplification primers. We thank Genomics Aotearoa for their 283 284 support. We thank the diagnostic laboratories that performed the initial RT-PCRs and referred samples for sequencing as well as the public health units for providing epidemiological data. We 285 thank the Nextstrain team for their support and timely global and local analysis. We thank all 286 287 those who have contributed SARS-CoV-2 sequences to GenBank and GISAID databases.

References 289

- 1 Wu, F. et al. A new coronavirus associated with human respiratory disease in China. 290 Nature 579, 265-269, doi:10.1038/s41586-020-2008-3 (2020). 291
- 292 2 Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273, doi:10.1038/s41586-020-2012-7 (2020). 293
- 3 Wu, J. T. et al. Estimating clinical severity of COVID-19 from the transmission dynamics in 294 295 Wuhan, China. Nat. Med. 26, 506-510, doi:10.1038/s41591-020-0822-7 (2020).
- 4 Russell, T. W. et al. Estimating the infection and case fatality ratio for coronavirus disease 296 297 (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise 298 ship, February 2020. Euro Surveill. 25, doi:10.2807/1560-7917.Es.2020.25.12.2000256 299 (2020).
- 5 Verity, R. et al. Estimates of the severity of coronavirus disease 2019: a model-based 300 analysis. Lancet Infect. Dis. 20, 669-677, doi:10.1016/s1473-3099(20)30243-7 (2020). 301
- 302 6 Ferretti, L. et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with
- 303 digital contact tracing. Science 368, eabb6936, doi:10.1126/science.abb6936 (2020).
- 7 Mizumoto, K., Kagaya, K., Zarebski, A. & Chowell, G. Estimating the asymptomatic 304 305 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro surveill. 25, 2000180, doi:10.2807/1560-306 307 7917.ES.2020.25.10.2000180 (2020).
- 8 Holmes, E. C. Novel 2019 coronavirus genome, https://virological.org/t/novel-2019-308 coronavirus-genome/319 (2020). 309
- Grubaugh, N. D. et al. Tracking virus outbreaks in the twenty-first century. Nat. Microbiol. 9 310 4, 10-19, doi:10.1038/s41564-018-0296-2 (2019). 311
- 312 10 Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinform 34, 4121-4123, doi:10.1093/bioinformatics/bty407 (2018). 313
- 11 Candido, D. d. S. et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science 314 315 eabd216, 10.1126/science.abd2161 (2020).
- 12 Filipe, A. D. S. et al. Genomic epidemiology of SARS-CoV-2 spread in Scotland highlights 316 the role of European travel in COVID-19 emergence. medRxiv, 2020.2006.2008.20124834, 317 doi:10.1101/2020.06.08.20124834 (2020). 318
- 319 13 Seemann, T. et al. Tracking the COVID-19 pandemic in Australia using genomics. medRxiv, 2020.2005.2012.20099929, doi:10.1101/2020.05.12.20099929 (2020). 320
- 14 Bedford, T. et al. Cryptic transmission of SARS-CoV-2 in Washington State. medRxiv, 321 2020.2004.2002.20051417. doi:10.1101/2020.04.02.20051417 (2020). 322
- 323 15 Eden, J.S. et al. An emergent clade of SARS-CoV-2 linked to returned travellers from Iran. 324 Virus Evol. 6, doi:10.1093/ve/veaa027 (2020).

325 16 Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 to assist genomic epidemiology. *bioRxiv*. 2020.2004.2017.046086. doi:10.1101/2020.04.17.046086 (2020). 326 17 Zhang, L. et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 327 328 shedding and increases infectivity. bioRxiv, 2020.2006.2012.148726, doi:10.1101/2020.06.12.148726 (2020). 329 18 Leclerc, Q. J. et al. What settings have been linked to SARS-CoV-2 transmission clusters? 330 331 Wellcome Open Res. 5, 83, doi:10.12688/wellcomeopenres.15889.2 (2020). 332 19 Loman, N. R., W; Rambaut, A. nCoV-2019 novel coronavirus bioinformatics protocol, https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html (2020). 333 20 Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina 334 sequence data. Bioinform. 30, 2114-2120, doi:10.1093/bioinformatics/btu170 (2014). 335 21 Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler 336 transform. Bioinform. 25, 1754-1760, doi:10.1093/bioinformatics/btp324 (2009). 337 22 Grubaugh, N. D. et al. An amplicon-based sequencing framework for accurately measuring 338 intrahost virus diversity using PrimalSeq and iVar. Genome Biol. 20, 8, 339 doi:10.1186/s13059-018-1618-7 (2019). 340 23 Picard Toolkit. Broad Institute, http://broadinstitute.github.io/picard/ (2019). 341 Li, H. A statistical framework for SNP calling, mutation discovery, association mapping 342 24 and population genetical parameter estimation from sequencing data. Bioinform. 27, 343 2987-2993, doi:10.1093/bioinformatics/btr509 (2011). 344 25 345 Garrison, E. Vcflib, a simple C++ library for parsing and manipulating VCF files. 346 https://github.com/vcflib/vcflib (2016). 347 26 Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges 1, 33-46, doi:10.1002/gch2.1018 (2017). 348 349 27 Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772-780, 350 doi:10.1093/molbev/mst010 (2013). 351 Nguyen, L.-T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective 28 352 353 stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol. 32, 268-274, doi:10.1093/molbev/msu300 (2015). 354 29 Hasegawa, M., Kishino, H. & Yano, T.-a. Dating of the human-ape splitting by a molecular 355 356 clock of mitochondrial DNA. J. Mol. Evol. 22, 160-174, doi:10.1007/BF02101694 (1985). 30 Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermiin, L. S. 357 ModelFinder: fast model selection for accurate phylogenetic estimates. Nat. Methods 14, 358 359 587-589, doi:10.1038/nmeth.4285 (2017).

- 360 31 Hoang, D. T., Chernomor, O., von Haeseler, A., Minh, B. Q. & Vinh, L. S. UFBoot2:
- Improving the ultrafast bootstrap approximation. *Mol. Biol. Evol.* 35, 518-522,
 doi:10.1093/molbev/msx28 (2017).
- 363 32 Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal structure
 364 of heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol.* 2,
 365 vew007, doi:10.1093/ve/vew007 (2016).
- 366 33 To, T. H., Jung, M., Lycett, S. & Gascuel, O. Fast dating using least-squares criteria and 367 algorithms. *Syst. Biol.* **65**, 82-97, doi:10.1093/sysbio/syv068 (2016).
- 368 34 Drummond, A. J. & Rambaut, A. BEAST: Bayesian evolutionary analysis by sampling trees.
 369 *BMC Evol. Biol.* 7, 214, doi:10.1186/1471-2148-7-214 (2007).
- 370 35 Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal
 371 origin of SARS-CoV-2. *Nat. Med.* 26, 450-452, doi:10.1038/s41591-020-0820-9 (2020).
- 372 36 Rambaut, A., Drummond, A. J., Xie, D., Baele, G. & Suchard, M. A. Posterior
- Summarization in Bayesian phylogenetics using tracer 1.7. Syst. Biol. 67, 901-904,
 doi:10.1093/sysbio/syy032 (2018).
- 375 37 EpiSurv: national notifiable disease surveillance database,
- 376 https://surv.esr.cri.nz/episurv/index.php, (2020).
- 37738Ho, S. Y., Duchêne, S. & Duchêne, D. Simulating and detecting autocorrelation of378molecular evolutionary rates among lineages. *Mol. Ecol. Resour.* **15**, 688-696,
- 379 doi:10.1111/1755-0998.12320 (2015).
- 39 Pybus, O. G. Preliminary analysis of SARS-CoV-2 importation & establishment of UK
 transmission lineages, https://virological.org/t/preliminary-analysis-of-sars-cov-2 importation-establishment-of-uk-transmission-lineages/507 (2020).
- 38340Stadler, T., Kühnert, D., Bonhoeffer, S. & Drummond, A. J. Birth–death skyline plot reveals384temporal changes of epidemic spread in HIV and hepatitis C virus (HCV). *Proc. Natl. Acad.*
- 385 Sci. USA **110**, 228-233, doi:10.1073/pnas.1207965110 (2013).
- He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat. Med.* 26, 672-675, doi:10.1038/s41591-020-0869-5 (2020).
- 388
- 389